micro-community-banner
Profile Image
  • Add Media
  • Saved

2yr
Effect of Combined Administration of Acyl-CoA: Cholesterol Acyltransferase 1 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist on a Rodent Model of Diet-Induced Obesity

Effect of Combined Administration of Acyl-CoA: Cholesterol Acyltransferase 1 Inhibitor and Glucagon-Like Peptide 1 Receptor Agonist on a Rodent Model of Diet-Induced Obesity

Source : https://www.sciencedirect.com/science/article/abs/pii/S0006291X23012585?via=ihub

A glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide was approved for the treatment of obesity by the Food and Drug Administration. Howev...

Collectively, these findings suggest combining semaglutide and avasimibe could be an effective approach to weight management.

Profile Image
  • Saved

2yr
Impact of a Pharmacist-Led Weight Management Service in a Cardiology Clinic

Impact of a Pharmacist-Led Weight Management Service in a Cardiology Clinic

Source : https://pubmed.ncbi.nlm.nih.gov/37944862/

Pharmacist-led management of GLP-1 RA in patients with obesity or overweight led to clinically significant weight loss and improvements in weight-related comorbidities.

Pharmacist-led management of GLP-1 RA in patients with obesity or overweight led to clinically significant weight loss and improvements in weight-related comorbidities.

Profile Image
  • Saved

2yr
Are We Ready to Recommend Capsaicin for Disorders Other Than Neuropathic Pain?

Are We Ready to Recommend Capsaicin for Disorders Other Than Neuropathic Pain?

Source : https://www.mdpi.com/2072-6643/15/20/4469

Capsaicin, a lipophilic, volatile compound, is responsible for the pungent properties of chili peppers. In recent years, a significant increase in investigations into its properties has allowed the production of...

Type 2 diabetes and dyslipidemia are closely linked to obesity and, consequently, could be beneficiated by capsaicin supplementation.

Profile Image
  • Saved

2yr
Effect of Long-Acting Versus Short-Acting Glucagon-Like Peptide-1 Receptor Agonists on Improving Body Weight and Related Metabolic Parameters in Type 2 Diabetes: a Head-to-Head Meta-Analysis

Effect of Long-Acting Versus Short-Acting Glucagon-Like Peptide-1 Receptor Agonists on Improving Body Weight and Related Metabolic Parameters in Type 2 Diabetes: a Head-to-Head Meta-Analysis

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615555/

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) showed great value in treating nonalcoholic fatty liver disease (NAFLD).

Long-acting GLP-1RAs may be more promise than short-acting GLP-1RAs in improving weight and related metabolic parameters.

Profile Image
  • Saved

2yr
Obesity treatment resources

A number of organizations recognize obesity as a chronic, relapsing, progressive disease, yet only a small percentage of patients can achieve their goals and maintain weight loss. Comprehensive care for obesity may involve energy deficit meal plans, physical activity, behavioral modification, consideration of circadian rhythms, and anti-obesity medications. However, providers may have limited time to engage in these and many report the need for more training.

What percent of your obese and overweight patients mention efforts to lose weight?
What resources (for patients or providers) have you found particularly useful in helping patients lose weight and maintain weight loss — or what additional ones would you like to see?

Profile Image

Show More Comments